The synthetic ursodeoxycholic acid-derivate BAR501 also increased insulin sensitivity and reduced hepatic steatosis, inflammation and fibrosis in mice with mild steatohepatitis [16,17]. This evidence concerns the gene INS and fatty liver disease.